当前位置:首页 - 行情中心 - 华恒生物(688639) - 财务分析 - 现金流量表

华恒生物

(688639)

  

流通市值:42.82亿  总市值:42.82亿
流通股本:2.50亿   总股本:2.50亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金788,113,324.342,730,918,428.862,139,169,844.581,412,441,457.52
  收到的税费返还22,940,184.9787,297,402.3778,172,268.5755,598,169.96
  收到其他与经营活动有关的现金5,747,219.8452,650,507.0635,578,875.0324,052,250.3
  经营活动现金流入小计816,800,729.152,870,866,338.292,252,920,988.181,492,091,877.78
  购买商品、接受劳务支付的现金661,444,327.192,186,529,162.151,717,363,072.231,130,890,211.75
  支付给职工以及为职工支付的现金106,062,798.56321,639,985.93233,611,314.08154,930,521.26
  支付的各项税费10,568,728.7255,282,272.447,546,495.1635,734,492.61
  支付其他与经营活动有关的现金25,652,501.35202,868,246.72139,658,595.7195,804,956.4
  经营活动现金流出小计803,728,355.822,766,319,667.22,138,179,477.181,417,360,182.02
  经营活动产生的现金流量净额13,072,373.33104,546,671.09114,741,51174,731,695.76
二、投资活动产生的现金流量:
  取得投资收益收到的现金-900,000--
  处置固定资产、无形资产和其他长期资产收回的现金净额-1,187,534.5137,856.717,558.7
  投资活动现金流入的平衡项目-000
  投资活动现金流入小计-2,087,534.5137,856.717,558.7
  购建固定资产、无形资产和其他长期资产支付的现金169,210,742.42636,725,336.47394,487,095.37253,699,111.44
  投资支付的现金-2,816,500--
  支付其他与投资活动有关的现金2,130,0006,001,566.5310,002,257.877,751,377.87
  投资活动现金流出小计171,340,742.42645,543,403404,489,353.24261,450,489.31
  投资活动产生的现金流量净额-171,340,742.42-643,455,868.49-404,451,496.54-261,432,930.61
三、筹资活动产生的现金流量:
  吸收投资收到的现金-5,075,560.445,075,560.445,075,560.44
  取得借款收到的现金667,003,401.881,717,908,246.631,453,017,760.95792,207,827.21
  筹资活动现金流入小计667,003,401.881,722,983,807.071,458,093,321.39797,283,387.65
  偿还债务支付的现金326,528,555.71,186,918,259.96990,237,333.19625,337,333.19
  分配股利、利润或偿付利息支付的现金14,537,247.8110,813,237.66101,748,248.8922,397,131.99
  支付其他与筹资活动有关的现金2,337,795.4616,032,937.34150,000-
  筹资活动现金流出小计343,403,598.961,313,764,434.961,092,135,582.08647,734,465.18
  筹资活动产生的现金流量净额323,599,802.92409,219,372.11365,957,739.31149,548,922.47
四、汇率变动对现金及现金等价物的影响-3,274,039.73-1,147,319.181,745,348.31,463,668.06
五、现金及现金等价物净增加额162,057,394.1-130,837,144.4777,993,102.07-35,688,644.32
  加:期初现金及现金等价物余额284,122,206.43414,959,350.9414,959,350.9414,959,350.9
  期末现金及现金等价物余额446,179,600.53284,122,206.43492,952,452.97379,270,706.58
补充资料:
  净利润-123,861,236.18-109,148,765.67
  资产减值准备-13,732,484.87-9,283,681.96
  固定资产和投资性房地产折旧-209,157,496.81-90,878,605.11
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-209,157,496.81-90,878,605.11
  无形资产摊销-5,640,802.57-2,777,323.29
  长期待摊费用摊销-6,239,814.97-2,535,438.33
  处置固定资产、无形资产和其他长期资产的损失--122,573.32-60,888.58
  固定资产报废损失-1,861,198.12-1,211,845.43
  财务费用-42,685,129.98-18,980,705.3
  投资损失-915,414.66-1,541,975.33
  递延所得税--24,500,028.45--15,057,860.67
  其中:递延所得税资产减少--58,757,523.06--20,719,497.63
    递延所得税负债增加-34,257,494.61-5,661,636.96
  存货的减少--138,942,755.94--111,323,784.44
  经营性应收项目的减少--73,479,827.55--38,925,797.58
  经营性应付项目的增加--66,780,968.05--4,484,194.76
  其他-3,881,707.55-3,881,707.55
  现金的期末余额-284,122,206.43-379,270,706.58
  减:现金的期初余额-414,959,350.9-414,959,350.9
  现金及现金等价物的净增加额--130,837,144.47--35,688,644.32
公告日期2026-04-232026-03-182025-10-282025-08-28
审计意见(境内)标准无保留意见
TOP↑